Avastin and Herceptin sales fuel Genentech income rise
Genentech reported a third-quarter net income that rose 56 percent aided by sales of its colon cancer drug Avastin (bevacizumab) ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.